Systematical identification of cell-specificity of CTCF-gene binding based on epigenetic modifications

The CCCTC-binding factor (CTCF) mediates transcriptional regulation and implicates epigenetic modifications in cancers. However, the systematically unveiling inverse regulatory relationship between CTCF and epigenetic modifications still remains unclear, especially the mechanism by which histone modification mediates CTCF binding. Here, we developed a systematic approach to investigate how epigenetic changes affect CTCF binding. Through integration analysis of CTCF binding in 30 cell lines, we concluded that CTCF generally binds with higher intensity in normal cell lines than that in cancers, and higher intensity in genome regions closed to transcription start sites. To facilitate the better understanding of their associations, we constructed linear mixed-effect models to analyze the effects of the epigenetic modifications on CTCF binding in four cancer cell lines and six normal cell lines, and identified seven epigenetic modifications as potential epigenetic patterns that influence CTCF binding intensity in promoter regions and six epigenetic modifications in enhancer regions. Further analysis of the effects in different locations revealed that the epigenetic regulation of CTCF binding was location-specific and cancer cell line-specific. Moreover, H3K4me2 and H3K9ac showed the potential association with immune regulation of disease. Taken together, our method can contribute to improve the understanding of the epigenetic regulation of CTCF binding and provide potential therapeutic targets for treating tumors associated with CTCF.

[1]  S. Fulda,et al.  Next‐generation sequencing reveals a novel role of lysine‐specific demethylase 1 in adhesion of rhabdomyosarcoma cells , 2019, International journal of cancer.

[2]  K. Myung,et al.  CTCF cooperates with CtIP to drive homologous recombination repair of double-strand breaks , 2019, Nucleic acids research.

[3]  J. Herrero,et al.  Enhancer accessibility and CTCF occupancy underlie asymmetric TAD architecture and cell type specific genome topology , 2019, Nature Communications.

[4]  Beisi Xu,et al.  Acute depletion of CTCF directly affects MYC regulation through loss of enhancer–promoter looping , 2019, Nucleic acids research.

[5]  Bianca J. Diaz,et al.  Identification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes. , 2019, Cell systems.

[6]  R. Pearson,et al.  First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematological Cancers: Results of a Phase I Dose Escalation Study. , 2019, Cancer discovery.

[7]  M. Vingron,et al.  Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks , 2019, Molecular systems biology.

[8]  Fei Zhang,et al.  Author Correction: Engineering of high-precision base editors for site-specific single nucleotide replacement , 2019, Nature Communications.

[9]  F. Altruda,et al.  Investigating the Connection Between Endogenous Heme Accumulation and COX2 Activity in Cancer Cells , 2019, Front. Oncol..

[10]  Chang-li Wu,et al.  Neural precursor cell expressed, developmentally downregulated 8 promotes tumor progression and predicts poor prognosis of patients with bladder cancer , 2018, Cancer science.

[11]  Wei Li,et al.  Gas41 links histone acetylation to H2A.Z deposition and maintenance of embryonic stem cell identity , 2018, Cell Discovery.

[12]  Jong-Wan Park,et al.  Inhibition of neddylation facilitates cell migration through enhanced phosphorylation of caveolin-1 in PC3 and U373MG cells , 2018, BMC Cancer.

[13]  Ji-Young Kim,et al.  KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin‐1‐mediated chromatin silencing , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  J. Peyron,et al.  Mitochondrial Transfer in the Leukemia Microenvironment. , 2017, Trends in cancer.

[15]  V. Sorrenti,et al.  Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia. , 2017, European journal of medicinal chemistry.

[16]  F. Tsai,et al.  Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury , 2017, Oncogene.

[17]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[18]  Yu Cao,et al.  The Nedd8 Non-covalent Binding Region in the Smurf HECT Domain is Critical to its Ubiquitn Ligase Function , 2017, Scientific Reports.

[19]  J. Yang,et al.  An ANCCA/PRO2000-miR-520a-E2F2 regulatory loop as a driving force for the development of hepatocellular carcinoma , 2016, Oncogenesis.

[20]  I. C. Allen,et al.  Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure. , 2016, The Journal of general virology.

[21]  J. Meléndez-Zajgla,et al.  Corrigendum: Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding , 2016, Scientific Reports.

[22]  J. Millán,et al.  Cellular Barriers after Extravasation: Leukocyte Interactions with Polarized Epithelia in the Inflamed Tissue , 2016, Mediators of inflammation.

[23]  Chromosomal instability as a prognostic marker in cervical cancer , 2015, BMC Cancer.

[24]  Xiaobo Zhou,et al.  Modeling the relationship of epigenetic modifications to transcription factor binding , 2015, Nucleic acids research.

[25]  Songbin Fu,et al.  RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma , 2015, Medical Oncology.

[26]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[27]  Yu Cao,et al.  The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis , 2014, Nature Communications.

[28]  M. Krem,et al.  The Kelch Protein KLHDC8B Guards against Mitotic Errors, Centrosomal Amplification, and Chromosomal Instability , 2012, The Journal of Biological Chemistry.

[29]  Supat Thongjuea,et al.  DNA-binding factor CTCF and long-range gene interactions in V(D)J recombination and oncogene activation. , 2012, Blood.

[30]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[31]  F. Recillas-Targa,et al.  Insulation of tumor suppressor genes by the nuclear factor CTCF. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[32]  Felix Krueger,et al.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..

[33]  Ruchir R. Shah,et al.  DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas , 2010, The Journal of experimental medicine.

[34]  L. Papucci,et al.  ζ‐Crystallin is a bcl‐2 mRNA binding protein involved in bcl‐2 overexpression in T‐cell acute lymphocytic leukemia , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  F. Recillas-Targa,et al.  Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines , 2010, Oncogene.

[36]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[37]  V. Corces,et al.  CTCF: Master Weaver of the Genome , 2009, Cell.

[38]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[39]  B. Emerson,et al.  Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. , 2009, Molecular cell.

[40]  R. Baayen,et al.  Mixed-effects modeling with crossed random effects for subjects and items , 2008 .

[41]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[42]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[43]  A. Feinberg.  Epigenetics at the epicenter of modern medicine. , 2008, JAMA.

[44]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[45]  G. Felsenfeld,et al.  We gather together: insulators and genome organization. , 2007, Current opinion in genetics & development.

[46]  M. Sata,et al.  X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues. , 2007, Oncology reports.

[47]  Wouter de Laat,et al.  CTCF mediates long-range chromatin looping and local histone modification in the beta-globin locus. , 2006, Genes & development.

[48]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[49]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[50]  Eric S. Lander,et al.  Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse , 2005, Cell.

[51]  Linda Hicke,et al.  Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. , 2003, Annual review of cell and developmental biology.

[52]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[53]  A. West,et al.  The Protein CTCF Is Required for the Enhancer Blocking Activity of Vertebrate Insulators , 1999, Cell.

[54]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  L. Montanaro,et al.  Nucleolar function and size in cancer cells. , 1998, The American journal of pathology.

[56]  A. Vostrov,et al.  The Zinc Finger Protein CTCF Binds to the APBβ Domain of the Amyloid β-Protein Precursor Promoter , 1997, The Journal of Biological Chemistry.

[57]  P. Neiman,et al.  An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes , 1996, Molecular and cellular biology.

[58]  P. Neiman,et al.  CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms , 1993, Molecular and cellular biology.

[59]  Victor V Lobanenkov,et al.  A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-flanking sequence of the chicken c-myc gene. , 1990, Oncogene.

[60]  R. Renkawitz,et al.  Modular structure of a chicken lysozyme silencer: Involvement of an unusual thyroid hormone receptor binding site , 1990, Cell.

[61]  Wei-Wei Zhang,et al.  Regulation of d-β-Hydroxybutyrate Dehydrogenase in Rat Hepatoma Cell Lines , 1989 .

[62]  W. W. Zhang,et al.  Regulation of D-beta-hydroxybutyrate dehydrogenase in rat hepatoma cell lines. , 1989, Cancer research.

[63]  S. R. Searle,et al.  Restricted Maximum Likelihood (REML) Estimation of Variance Components in the Mixed Model , 1976 .